无创评分系统在评估非酒精性脂肪性肝病患者死亡及肝脏相关终点风险中的准确性
该回顾性分析纳入瑞典2家医院1971至2009年活检证实的646例非酒精性脂肪性肝病患者,计算NFS、FIB-4、APRI和BARD评分并随访至2014年底。平均随访19.9±8.7年期间发生214例死亡和76例严重肝病;NFS和FIB-4对全因死亡和严重肝病的预测准确性最高,但AUROC值不足以用于临床,需要新的评分系统。
要点
- NFS和FIB-4对全因死亡的AUROC均为0.72,对严重肝病的AUROC均为0.72。
- BARD和APRI预测准确性较低,APRI对全因死亡的AUROC仅0.52。
- 所有评分的C统计量仅为中等预测能力,AUROC值不足以用于临床。
核心结论
- 在646例活检证实的非酒精性脂肪性肝病患者中,NFS和FIB-4评分对全因死亡或严重肝病风险的判定最准确。
- 然而这些评分系统的AUROC值不够高,不足以在临床中使用;需要新的系统来确定非酒精性脂肪性肝病患者的预后。
研究设计与样本
- 回顾性分析,纳入瑞典2家医院1971年至2009年招募的646例活检证实的非酒精性脂肪性肝病患者。
- 在肝活检时计算NAFLD纤维化评分(NFS)、FIB-4、APRI和BARD评分,并据此将患者分为进展期纤维化低、中、高风险。
- 通过链接国家登记处随访至2014年底,确定全因死亡和严重肝病(肝硬化、失代偿性肝病、肝衰竭或肝细胞癌)。
- 采用Cox回归、受试者工作特征曲线下面积(AUROC)和C统计量分析各评分系统的预测能力。
主要发现
- 平均随访19.9±8.7年期间,共发生214例死亡和76例严重肝病。
- 对全因死亡,AUROC值:NFS为0.72(95%CI,0.68-0.76);FIB-4为0.72(95%CI,0.68-0.76);BARD为0.62(95%CI,0.58-0.66);APRI为0.52(95%CI,0.47-0.57)。
- 对严重肝病,AUROC值:NFS为0.72(95%CI,0.66-0.78);FIB-4为0.72(95%CI,0.66-0.79);BARD为0.62(95%CI,0.55-0.69);APRI为0.69(95%CI,0.63-0.76)。
- 所有评分的C统计量对结局的预测能力均为中等。
关键数值与推荐
- NFS对全因死亡的AUROC为0.72(95%CI,0.68-0.76),对严重肝病的AUROC为0.72(95%CI,0.66-0.78)。
- FIB-4对全因死亡的AUROC为0.72(95%CI,0.68-0.76),对严重肝病的AUROC为0.72(95%CI,0.66-0.79)。
- BARD对全因死亡的AUROC为0.62(95%CI,0.58-0.66),对严重肝病的AUROC为0.62(95%CI,0.55-0.69)。
- APRI对全因死亡的AUROC为0.52(95%CI,0.47-0.57),对严重肝病的AUROC为0.69(95%CI,0.63-0.76)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Several non-invasive scoring systems have been developed to determine risk of advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). We examined the association between 4 scoring systems and incident severe liver disease and overall mortality in a large cohort of patients with biopsy-proven NAFLD. METHODS: We performed a retrospective analysis of data from 646 patients with biopsy-proven NAFLD, recruited from 2 hospitals in Sweden, from 1971 through 2009. The NAFLD fibrosis score (NFS), FIB-4, APRI, and BARD scores were calculated at the time of the liver biopsy. Based on each score, patients were assigned to categories of low, intermediate, or high risk for advanced fibrosis. Overall mortality and severe liver disease (cirrhosis, decompensated liver disease, liver failure, or hepatocellular carcinoma) were ascertained through linkage with national registers until the end of 2014. Cox regression, area under the receiver operating characteristic (AUROC) curve, and C-statistic analyses were used to study the predictive capacity of each scoring system. RESULTS: During a mean follow-up time of 19.9±8.7 years, there were 214 deaths and 76 cases of severe liver disease. For overall mortality, AUROC curve values were: NFS, 0.72 (95% CI, 0.68-0.76); FIB-4, 0.72 (95% CI, 0.68-0.76); BARD, 0.62 (95% CI, 0.58-0.66); and APRI, 0.52 (95% CI, 0.47-0.57). For severe liver disease, AUROC curve values were: NFS, 0.72 (95% CI, 0.66-0.78); FIB-4, 0.72 (95% CI, 0.66-0.79); BARD, 0.62 (95% CI, 0.55-0.69); APRI, 0.69 (95% CI, 0.63-0.76). C-statistics for all scores were of moderate capacity to predict outcomes. CONCLUSIONS: In a retrospective analysis of data from 646 patients with biopsy-proven NAFLD, we found the NFS and the FIB-4 scores to most accurately determine risk of overall death or severe liver disease. However, the AUROC values for these scoring systems are not high enough for use in the clinic; new systems are needed to determine prognoses of patients with NAFLD.
引用
- Hagström H, Nasr P, Ekstedt M, et al. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2018. PMID: 30471458. doi:10.1016/j.cgh.2018.11.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。